Trevogrumab

Trevogrumab, known as REGN1033, is a monoclonal antibody that functions by inhibiting the activity of myostatin, a protein that limits muscle growth. Interest in Trevogrumab started around its potential to modulate muscle mass in various conditions. This peptide has been particularly noted for its ability to target the myostatin pathway, which plays a significant role in muscle regulation. Researchers have explored its effects on muscle tissue systems, hoping to unlock therapeutic applications for muscle-wasting diseases. Today, it is primarily studied for its effects on:

• Muscle-wasting conditions
• Myostatin inhibition
• Muscle mass regulation
• Athletic performance enhancement
• Sarcopenia

Additionally, Trevogrumab is being investigated for its applications in sports medicine.

PeptideSource editorial · Updated Jul 18, 2026